

# Safety of Bevacizumab in Patients With Non-“Small-C

Journal of Clinical Oncology

27, 5255-5261

DOI: 10.1200/jco.2009.22.0616

Citation Report

#	ARTICLE	IF	CITATIONS
1	OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB. <i>Neurology</i> , 2009, 73, 1924-1926.	1.5	54
2	Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors. <i>Anti-Cancer Drugs</i> , 2010, 21, 151-168.	0.7	9
4	Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. <i>Current Opinion in Oncology</i> , 2010, 22, 79-85.	1.1	6
5	Antiangiogenic Agents and Vascular Disrupting Agents for the Treatment of Lung Cancer: A Review. <i>Journal of Thoracic Oncology</i> , 2010, 5, 129-139.	0.5	13
6	Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2010, 8, 740-801.	2.3	606
7	2. Bevacizumab (AVASTIN®). <i>The Journal of the Japanese Society of Internal Medicine</i> , 2010, 99, 1605-1610.	0.0	0
8	Modern Multidisciplinary Management of Brain Metastases. <i>Current Oncology Reports</i> , 2010, 12, 34-40.	1.8	37
9	Efficacy and safety of bevacizumab in active brain metastases from non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2010, 100, 443-447.	1.4	100
10	Hemorrhage of brain metastasis from non-small cell lung cancer post gefitinib therapy: two case reports and review of the literature. <i>BMC Cancer</i> , 2010, 10, 49.	1.1	20
11	Anti-angiogenesis drugs in lung cancer. <i>Respirology</i> , 2010, 15, 387-392.	1.3	7
12	Targeted Therapies for Non-Small Cell Lung Cancer: An Evolving Landscape. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 1931-1944.	1.9	74
13	Therapy and prophylaxis of brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2010, 10, 1763-1777.	1.1	40
14	Bevacizumab Safety in Patients with Central Nervous System Metastases. <i>Clinical Cancer Research</i> , 2010, 16, 269-278.	3.2	236
16	The Emerging Role of Histology in the Choice of First-Line Treatment of Advanced Non-Small Cell Lung Cancer: Implication in the Clinical Decision-Making. <i>Current Medicinal Chemistry</i> , 2010, 17, 1030-1038.	1.2	24
17	Novel Agents in the Management of Lung Cancer. <i>Current Medicinal Chemistry</i> , 2010, 17, 4291-4325.	1.2	21
18	OPTIC NEUROPATHY IN PATIENTS WITH GLIOBLASTOMA RECEIVING BEVACIZUMAB. <i>Neurology</i> , 2010, 75, 289-290.	1.5	5
19	Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2010, 70, 233-246.	0.9	15
20	Carboplatin/Pemetrexed/Bevacizumab in the Treatment of Patients With Advanced Non-Small-Cell Lung Cancer: A Single-Institution Experience. <i>Clinical Lung Cancer</i> , 2010, 11, 192-197.	1.1	13

#	ARTICLE	IF	CITATIONS
21	Parameters for individualizing systemic therapy in non-small cell lung cancer. Drug Resistance Updates, 2010, 13, 196-204.	6.5	15
22	Translational research in brain metastasis is identifying molecular pathways that may lead to the development of new therapeutic strategies. European Journal of Cancer, 2010, 46, 1204-1210.	1.3	73
23	Systemic treatment in breast-cancer patients with brain metastasis. Expert Opinion on Pharmacotherapy, 2010, 11, 1089-1100.	0.9	40
24	Antiangiogenic Agents in Combination with Chemotherapy in Patients with Advanced Non-Small Cell Lung Cancer. Cancer Investigation, 2011, 29, 325-337.	0.6	66
26	Medical Management of Brain Metastases. Neurosurgery Clinics of North America, 2011, 22, 27-36.	0.8	8
27	Bevacizumab in non-small-cell lung cancer: a review. Expert Review of Anticancer Therapy, 2011, 11, 1163-1179.	1.1	30
28	The biology of brain metastases—translation to new therapies. Nature Reviews Clinical Oncology, 2011, 8, 344-356.	12.5	443
29	Therapeutic advances in non-small cell lung cancer: Highlights from the annual clinical cancer conferences. Community Oncology, 2011, 8, 5-16.	0.2	0
30	Angiogenesis and Lung Cancer. Medical Radiology, 2011, , 17-41.	0.0	1
31	Systemic Therapy for Lung Cancer for the Radiation Oncologist. Medical Radiology, 2011, , 247-266.	0.0	0
32	Personalized Therapy in Lung Cancer: Focused on Molecular Targeted Therapy. Journal of Lung Cancer, 2011, 10, 1.	0.2	2
33	Phase II Study of Sunitinib in Patients with Non-small Cell Lung Cancer and Irradiated Brain Metastases. Journal of Thoracic Oncology, 2011, 6, 1260-1266.	0.5	46
34	Targeted therapy: An evolving world of lung cancer. Respiriology, 2011, 16, 13-21.	1.3	21
35	Brain metastases as preventive and therapeutic targets. Nature Reviews Cancer, 2011, 11, 352-363.	12.8	308
36	Vascular phenotypes in primary non-small cell lung carcinomas and matched brain metastases. British Journal of Cancer, 2011, 104, 1877-1881.	2.9	53
37	Clinical Evidence on the Undertreatment of Older and Poor Performance Patients Who Have Advanced Non-Small-Cell Lung Cancer: Is There a Role for Targeted Therapy in These Cohorts?. Clinical Lung Cancer, 2011, 12, 272-279.	1.1	22
38	Preliminary experience of whole-brain radiation therapy (WBRT) in breast cancer patients with brain metastases previously treated with bevacizumab-based chemotherapy. Journal of Neuro-Oncology, 2011, 105, 401-408.	1.4	8
39	Revisiting the role of molecular targeted therapies in patients with brain metastases. Journal of Neuro-Oncology, 2011, 105, 467-474.	1.4	11

#	ARTICLE	IF	CITATIONS
41	Cerebrovascular Events After Bevacizumab Treatment: An Early and Severe Complication. <i>Neurocritical Care</i> , 2011, 15, 421-427.	1.2	34
42	Radiation therapy for brain metastases in breast cancer patients. <i>Breast Cancer</i> , 2011, 18, 244-251.	1.3	31
43	Predictive Factors for the Development of Brain Metastasis in Advanced Unresectable Metastatic Melanoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011, 34, 603-610.	0.6	60
44	Phase I Study of NGR-hTNF, a Selective Vascular Targeting Agent, in Combination with Cisplatin in Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2011, 17, 1964-1972.	3.2	53
45	Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues. <i>Current Medicinal Chemistry</i> , 2012, 19, 961-971.	1.2	19
46	Targeting Angiogenesis for Treatment of NSCLC Brain Metastases. <i>Current Cancer Drug Targets</i> , 2012, 12, 289-299.	0.8	17
47	Targeted Therapeutics in Treatment of Children and Young Adults with Solid Tumors: an Expert Survey and Review of the Literature. <i>Klinische Padiatrie</i> , 2012, 224, 124-131.	0.2	15
48	Management of treatment-associated toxicities of anti-angiogenic therapy in patients with brain tumors. <i>Neuro-Oncology</i> , 2012, 14, 1203-1214.	0.6	55
49	Intracranial hemorrhage in patients with cancer treated with bevacizumab: the Memorial Sloan-Kettering experience. <i>Annals of Oncology</i> , 2012, 23, 458-463.	0.6	63
50	Targeted therapy in brain metastasis. <i>Current Opinion in Oncology</i> , 2012, 24, 679-686.	1.1	64
52	Bevacizumab is an active agent for recurrent high-grade glioma, but do we need randomized controlled trials?. <i>Anti-Cancer Drugs</i> , 2012, 23, 579-583.	0.7	7
53	Non-Small Cell Lung Cancer. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2012, 10, 1236-1271.	2.3	312
55	The Impact of Local and Regional Disease Extent on Overall Survival in Patients With Advanced Stage IIIB/IV Non-Small Cell Lung Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e385-e392.	0.4	19
56	Metastasi cerebrali. <i>EMC - Neurologia</i> , 2012, 12, 1-22.	0.0	0
59	Targeted therapy of non-small-cell lung carcinoma. <i>Therapeutic Advances in Respiratory Disease</i> , 2012, 6, 41-56.	1.0	4
60	Current and emerging medical treatments for non-small cell lung cancer: A primer for pulmonologists. <i>Respiratory Medicine</i> , 2012, 106, 473-492.	1.3	8
61	Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer. <i>Journal of Neuro-Oncology</i> , 2012, 109, 229-238.	1.4	17
62	Antiangiogenic agents as second-line therapy for advanced non-small cell lung cancer. <i>Cancer Letters</i> , 2012, 321, 101-109.	3.2	8

#	ARTICLE	IF	CITATIONS
63	Targeting VEGF in lung cancer. Expert Opinion on Therapeutic Targets, 2012, 16, 395-406.	1.5	37
64	Central Nervous System Complications of Cancer Therapy. The Journal of Supportive Oncology, 2012, 10, 133-141.	2.3	25
66	MO19390 (SAiL): Bleeding events in a phase IV study of first-line bevacizumab with chemotherapy in patients with advanced non-squamous NSCLC. Lung Cancer, 2012, 76, 373-379.	0.9	31
67	An evidence-based review of the incidence of CNS bleeding with anti-VEGF therapy in non-small cell lung cancer patients with brain metastases. Lung Cancer, 2012, 78, 1-7.	0.9	43
68	Prolonged activity of bevacizumab in adenocarcinoma of the lung with multiple brain metastases. Medical Oncology, 2012, 29, 2619-2622.	1.2	5
69	Antiangiogenic therapy in the management of brain tumors: a clinical overview. Cancer Chemotherapy and Pharmacology, 2012, 70, 353-363.	1.1	3
70	Central Nervous System Metastasis, the Biological Basis and Clinical Considerations. Cancer Metastasis - Biology and Treatment, 2012, , .	0.1	9
71	Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial. OncoTargets and Therapy, 2012, 5, 185.	1.0	26
72	Brain Metastases Research 1990â€“2010: Pattern of Citation and Systematic Review of Highly Cited Articles. Scientific World Journal, The, 2012, 2012, 1-9.	0.8	7
73	Antiangiogenic agents in the management of non-small cell lung cancer. Cancer Biology and Therapy, 2012, 13, 247-263.	1.5	63
74	The Therapeutic Management of Bleeding and Thrombotic Disorders Complicating CNS Malignancies. Current Treatment Options in Oncology, 2012, 13, 451-464.	1.3	10
75	Predicting the need for palliative thoracic radiation after firstâ€“line chemotherapy for advanced nonsmall cell lung carcinoma. Cancer, 2012, 118, 2744-2751.	2.0	6
76	Developmental antiangiogenic agents for the treatment of Non-Small Cell Lung Cancer (NSCLC). Investigational New Drugs, 2012, 30, 1802-1811.	1.2	12
77	The Double Edged Sword of Bleeding and Clotting from VEGF Inhibition in Renal Cancer Patients. Current Oncology Reports, 2012, 14, 295-306.	1.8	38
80	Safety Profile and Tolerability of Antiangiogenic Agents in Nonâ€“Small-Cell Lung Cancer. Clinical Lung Cancer, 2012, 13, 96-106.	1.1	16
81	Challenges in the current antiangiogenic treatment paradigm for patients with non-small cell lung cancer. Critical Reviews in Oncology/Hematology, 2012, 82, 200-212.	2.0	12
82	Treatment of Brain Metastases: Chemotherapy. Current Oncology Reports, 2012, 14, 85-90.	1.8	32
83	Anti-Angiogenic Therapy in High-Grade Glioma (Treatment and Toxicity). Current Treatment Options in Neurology, 2013, 15, 328-337.	0.7	15

#	ARTICLE	IF	CITATIONS
84	Bevacizumab and central nervous system (CNS) hemorrhage. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1561-1565.	1.1	57
85	Bevacizumab in older patients with advanced colorectal or breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 41-54.	2.0	10
86	Optimal Management of Brain Metastases from Breast Cancer. <i>CNS Drugs</i> , 2013, 27, 121-134.	2.7	27
87	Bevacizumab in Advanced NSCLC: Chemotherapy Partners and Duration of Use. <i>Current Treatment Options in Oncology</i> , 2013, 14, 595-609.	1.3	12
89	Targeting tumor neovasculature in non-small-cell lung cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 86, 130-142.	2.0	31
90	Innovative Therapeutic Strategies in the Treatment of Brain Metastases. <i>International Journal of Molecular Sciences</i> , 2013, 14, 2135-2174.	1.8	41
92	Revisiting the role of systemic therapies in patients with metastatic melanoma to the CNS. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 559-567.	1.1	6
93	Therapeutic strategy for non-small-cell lung cancer patients with brain metastases (Review). <i>Biomedical Reports</i> , 2013, 1, 691-696.	0.9	11
94	Non-Small-Cell Lung Cancer: Treatment of Late Stage Disease: Chemotherapeutics and New Frontiers. <i>Seminars in Interventional Radiology</i> , 2013, 30, 191-198.	0.3	67
95	Drug Review: Safety and Efficacy of Bevacizumab for Glioblastoma and Other Brain Tumors. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 587-595.	0.6	57
96	Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. <i>Annals of Oncology</i> , 2013, 24, 3004-3011.	0.6	25
97	Antiangiogenic agents and chemotherapy in advanced non-small cell lung cancer: a clinical perspective. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 1193-1206.	1.1	2
98	A Patient With Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer With Development of Leptomeningeal Carcinomatosis While on Targeted Treatment With Crizotinib. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2013, 11, 389-394.	2.3	14
99	Treatment of Stage IV Non-small Cell Lung Cancer. <i>Chest</i> , 2013, 143, e341S-e368S.	0.4	180
100	Angiogenesis and Lung Cancer. , 2013, , .		1
101	Bispecific Targeted Toxin DTATEGF Against Metastatic NSCLC Brain Tumors. , 2014, , 157-167.		0
102	Antiangiogenesis in Cancer Therapy. , 2014, , .		0
103	How should we manage bevacizumab toxicity in lung cancer patients?. <i>Lung Cancer Management</i> , 2014, 3, 355-363.	1.5	0

#	ARTICLE	IF	CITATIONS
104	Brain metastases in non-small-cell lung cancer: better outcomes through current therapies and utilization of molecularly targeted approaches. <i>CNS Oncology</i> , 2014, 3, 61-75.	1.2	9
105	The role of systemic and targeted therapies in brain metastases. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 93-103.	1.1	6
106	The search for novel therapeutic strategies in the treatment of recurrent glioblastoma multiforme. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 955-964.	1.1	17
107	First-line therapeutic options for advanced non-small-cell lung cancer in the molecular medicine era. <i>Future Oncology</i> , 2014, 10, 1081-1093.	1.1	5
108	Bevacizumab-Based Therapy for Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Preliminary Results. <i>Chemotherapy</i> , 2014, 60, 294-299.	0.8	21
109	The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 74, 1159-1166.	1.1	49
110	Treatment of Brain Metastases. <i>Oncology</i> , 2014, 87, 321-329.	0.9	20
111	Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. <i>Therapeutic Advances in Medical Oncology</i> , 2014, 6, 101-114.	1.4	178
112	Extending Survival of Stage IV Non-Small Cell Lung Cancer. <i>Seminars in Oncology</i> , 2014, 41, 69-92.	0.8	34
113	Targeted Therapies in Brain Metastases. <i>Current Treatment Options in Neurology</i> , 2014, 16, 276.	0.7	42
114	Safety of bevacizumab in patients with malignant gliomas: a systematic review. <i>Neurological Sciences</i> , 2014, 35, 83-89.	0.9	17
115	The role of the tumor-microenvironment in lung cancer-metastasis and its relationship to potential therapeutic targets. <i>Cancer Treatment Reviews</i> , 2014, 40, 558-566.	3.4	350
116	Brain Metastases in Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2014, 15, 249-257.	1.1	31
117	REBECA: a phase I study of bevacizumab and whole-brain radiation therapy for the treatment of brain metastasis from solid tumours. <i>Annals of Oncology</i> , 2014, 25, 2351-2356.	0.6	51
118	Bevacizumab: A Review of Its Use in Advanced Cancer. <i>Drugs</i> , 2014, 74, 1891-1925.	4.9	142
119	Brain metastases in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 173-183.	1.1	8
120	Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 1643-1658.	0.9	17
122	Prolonged Survival of Patients With Non-Small-Cell Lung Cancer With Leptomeningeal Carcinomatosis in the Modern Treatment Era. <i>Clinical Lung Cancer</i> , 2014, 15, 202-206.	1.1	68

#	ARTICLE	IF	CITATIONS
123	Indications and limitations of chemotherapy and targeted agents in non-small cell lung cancer brain metastases. <i>Cancer Treatment Reviews</i> , 2014, 40, 716-722.	3.4	123
124	Brain metastasis: New opportunities to tackle therapeutic resistance. <i>Molecular Oncology</i> , 2014, 8, 1120-1131.	2.1	37
125	Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: An overview of the literature. <i>Cancer Treatment Reviews</i> , 2014, 40, 951-959.	3.4	43
126	Bevacizumab for Critical Brain Metastases in a Patient with Pulmonary Pleomorphic Carcinoma. <i>Internal Medicine</i> , 2014, 53, 1813-1818.	0.3	3
128	Efficacy of XELOX plus Bevacizumab in Brain Metastasis from Rectal Cancer. <i>Case Reports in Oncology</i> , 2014, 7, 117-121.	0.3	6
130	Bevacizumab in Combination with Chemotherapy or Molecularly Targeted Agents for Non-Small-Cell Lung Cancer with Brain Metastases. <i>Journal of Thoracic Oncology</i> , 2015, 10, e76.	0.5	0
131	Vascular endothelial growth factor blockade alters magnetic resonance imaging biomarkers of vascular function and decreases barrier permeability in a rat model of lung cancer brain metastasis. <i>Fluids and Barriers of the CNS</i> , 2015, 12, 5.	2.4	27
132	Safety profile of combined therapy inhibiting <scp>EFGR</scp> and <scp>VEGF</scp> pathways in patients with advanced non-small cell lung cancer: A meta-analysis of 15 phase II/III randomized trials. <i>International Journal of Cancer</i> , 2015, 137, 409-419.	2.3	22
133	Antiangiogéniques en cancérologie thoracique : critères de prescription et gestion des effets indésirables. <i>Revue Des Maladies Respiratoires Actualites</i> , 2015, 7, 414-422.	0.0	0
134	Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience. <i>Clinical Lung Cancer</i> , 2015, 16, e229-e234.	1.1	15
135	The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: an Update. <i>Current Oncology Reports</i> , 2015, 17, 26.	1.8	44
136	Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2601-2613.	0.9	22
137	Treatment of Brain Metastases. <i>Journal of Clinical Oncology</i> , 2015, 33, 3475-3484.	0.8	318
139	Anti-angiogenetic therapies for central nervous system metastases from non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2016, 5, 610-627.	1.3	13
140	Treatment of brain metastases of lung cancer in the era of precision medicine. <i>Frontiers in Bioscience - Elite</i> , 2016, 8, 219-232.	0.9	9
141	Systemic Immunotherapy for the Treatment of Brain Metastases. <i>Frontiers in Oncology</i> , 2016, 6, 49.	1.3	66
142	Systemic treatment of non-small cell lung cancer brain metastases. <i>Wspolczesna Onkologia</i> , 2016, 5, 352-357.	0.7	4
144	Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases. <i>Oncology Letters</i> , 2016, 12, 4635-4642.	0.8	16



#	ARTICLE	IF	CITATIONS
145	Challenges in the treatment of hormone receptor-positive, HER2-negative metastatic breast cancer with brain metastases. <i>Cancer and Metastasis Reviews</i> , 2016, 35, 323-332.	2.7	15
146	Retrospective analysis of bevacizumab-induced hypertension and clinical outcome in patients with colorectal cancer and lung cancer. <i>Cancer Medicine</i> , 2016, 5, 1381-1387.	1.3	32
147	Bevacizumab plus chemotherapy versus chemotherapy alone for preventing brain metastasis derived from advanced lung cancer. <i>Journal of Chemotherapy</i> , 2016, 28, 218-224.	0.7	25
148	A dynamic in vivo-like organotypic blood-brain barrier model to probe metastatic brain tumors. <i>Scientific Reports</i> , 2016, 6, 36670.	1.6	147
149	Pemetrexed/cisplatin as first-line chemotherapy for advanced lung cancer with brain metastases. <i>Medicine (United States)</i> , 2016, 95, e4401.	0.4	12
150	Incorporation of Antiangiogenic Therapy Into the Non-“Small-Cell Lung Cancer Paradigm. <i>Clinical Lung Cancer</i> , 2016, 17, 493-506.	1.1	16
151	Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1627-1643.	0.5	67
152	Systemic therapies in the treatment of non-small-cell lung cancer brain metastases. <i>Future Oncology</i> , 2016, 12, 1045-1058.	1.1	10
153	Bevacizumab Prevents Brain Metastases Formation in Lung Adenocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 702-710.	1.9	103
154	Targeted Therapies for the Treatment of Brain Metastases in Solid Tumors. <i>Targeted Oncology</i> , 2016, 11, 263-275.	1.7	17
155	Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. <i>Journal of Gastrointestinal Cancer</i> , 2016, 47, 82-88.	0.6	15
156	Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine. <i>CNS Oncology</i> , 2017, 6, 139-151.	1.2	12
157	Systemic Treatment of Brain Metastases. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 157-176.	0.9	8
158	First-Line Systemic Therapy for Non-“Small Cell Lung Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 59-70.	0.9	9
159	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. <i>Medical Oncology</i> , 2017, 34, 121.	1.2	12
160	Bevacizumab in advanced lung cancer: state of the art. <i>Future Oncology</i> , 2017, 13, 2515-2535.	1.1	53
161	Bevacizumab Plus Radiosurgery for Nonsquamous Non-“Small Cell Lung Cancer Patients with Brain Metastases: Safe Combination?. <i>World Neurosurgery</i> , 2017, 107, 1047.e1-1047.e4.	0.7	8
162	Brain metastases from non-small cell lung carcinoma: Changing concepts for improving patients’™ outcome. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 116, 32-37.	2.0	7

#	ARTICLE	IF	CITATIONS
163	Bevacizumab in the treatment of NSCLC: patient selection and perspectives. Lung Cancer: Targets and Therapy, 2017, Volume 8, 259-269.	1.3	37
164	Leptomeningeal disease: current diagnostic and therapeutic strategies. Oncotarget, 2017, 8, 73312-73328.	0.8	130
165	Anti-angiogenic therapies in brain metastases. Memo - Magazine of European Medical Oncology, 2018, 11, 14-17.	0.3	26
166	Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis. Journal of Neuro-Oncology, 2018, 137, 49-56.	1.4	21
167	Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 310-320.	2.3	476
168	Bevacizumab in Combination with Platinum-Based Chemotherapy in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with or without Brain Metastases: A French Cohort Study (EOLE). Oncology, 2018, 94, 55-64.	0.9	16
169	Neurological Complications of Lung Cancer. , 2018, , 417-434.		0
170	A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. Journal of Thoracic Disease, 2018, 10, 219-227.	0.6	6
171	First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. Journal of Oncology Practice, 2018, 14, 529-535.	2.5	41
172	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. BioMed Research International, 2018, 2018, 1-8.	0.9	24
173	Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?. Critical Reviews in Oncology/Hematology, 2018, 128, 19-29.	2.0	14
174	Management of Leptomeningeal Metastases in Non-oncogene Addicted Non-small Cell Lung Cancer. Frontiers in Oncology, 2018, 8, 278.	1.3	15
175	Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non-Small Cell Lung Cancer. JAMA Oncology, 2019, 5, 1448.	3.4	94
176	Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non-Small-Cell Lung Cancer: ECOG-ACRIN 5508. Journal of Clinical Oncology, 2019, 37, 2360-2367.	0.8	52
177	Efficacy and safety of bevacizumab combined with chemotherapy in symptomatic brain metastases from lung adenocarcinoma: a retrospective analysis. Journal of Thoracic Disease, 2019, 11, 4725-4734.	0.6	6
178	Bevacizumab for the treatment of non-small cell lung cancer patients with synchronous brain metastases. Scientific Reports, 2019, 9, 17792.	1.6	13
179	Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases. Cancer Management and Research, 2019, Volume 11, 10083-10092.	0.9	9
180	Phase II trial of carboplatin and bevacizumab in patients with breast cancer brain metastases. Breast Cancer Research, 2020, 22, 131.	2.2	31

#	ARTICLE	IF	CITATIONS
181	Systemic treatment of brain metastases in non-small cell lung cancer. <i>European Journal of Cancer</i> , 2020, 132, 187-198.	1.3	61
182	Phase III randomized study of carboplatin pemetrexed with or without bevacizumab with initial versus late progression cerebral radiotherapy in advanced non squamous non-small cell lung cancer with asymptomatic brain metastasis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110069.	1.4	2
183	Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis. <i>Cell Death and Disease</i> , 2021, 12, 106.	2.7	16
184	Rapid Growth of Anterior Chamber Metastasis From Presumed Non-Small Cell Lung Cancer During Targeted Therapy, Responding to a Single Intracameral Injection of Anti-Vascular Endothelial-Derived Growth Factor. <i>JAMA Ophthalmology</i> , 2021, 139, e204096.	1.4	2
185	Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non-small cell lung cancer patients with asymptomatic brain metastases. <i>Investigational New Drugs</i> , 2021, 39, 1598-1603.	1.2	1
186	Maintenance treatment of combination with bevacizumab vs single agent for advanced non-squamous non-small cell lung cancer. <i>Medicine (United States)</i> , 2021, 100, e26862.	0.4	2
187	Stereotactic radiosurgery with whole brain radiotherapy combined with bevacizumab in the treatment of brain metastases from NSCLC. <i>International Journal of Neuroscience</i> , 2023, 133, 334-341.	0.8	4
188	Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. <i>Cancer Cell</i> , 2021, 39, 1279-1291.e3.	7.7	99
189	Supportive Medical Management of Brain Metastases Patients Including Treatment Complications. , 2020, , 31-51.		3
190	Bevacizumab for non-small cell lung cancer patients with brain metastasis: A meta-analysis. <i>Open Medicine (Poland)</i> , 2020, 15, 589-597.	0.6	9
191	Greater efficacy of chemotherapy plus bevacizumab compared to chemo- and targeted therapy alone on non-small cell lung cancer patients with brain metastasis. <i>Oncotarget</i> , 2016, 7, 3635-3644.	0.8	24
192	Molecular Mechanisms and Targeted Therapies Including Immunotherapy for Non-Small Cell Lung Cancer. <i>Current Cancer Drug Targets</i> , 2019, 19, 595-630.	0.8	61
193	Antiangiogenic agents for the treatment of nonsmall cell lung cancer: characterizing the molecular basis for serious adverse events. <i>Cancer Investigation</i> , 2011, 29, 460-71.	0.6	11
194	Intracranial hemorrhage in patients treated with bevacizumab: Report of two cases. <i>World Journal of Gastroenterology</i> , 2011, 17, 4440.	1.4	10
196	Update on anti-angiogenic therapy in non-small cell lung cancer: Are we making progress?. <i>Journal of Thoracic Disease</i> , 2011, 3, 19-29.	0.6	31
197	Treatment of advanced non small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2011, 3, 122-33.	0.6	99
198	Intracameral Bevacizumab Administered for Non-Small Cell Lung Cancer Metastasis to Iris. <i>Clinics and Practice</i> , 2011, 1, e39.	0.6	5
200	Safety of Bevacizumab-containing chemotherapy in Non-small-cell Lung Cancer Patients with Brain metastases. <i>Annals of Cancer Research and Therapy</i> , 2012, 20, 47-51.	0.1	3

#	ARTICLE	IF	CITATIONS
201	Non-“Small Cell Lung Cancer. Journal of the National Comprehensive Cancer Network: JNCCN, 2008, 6, 228.	2.3	343
202	Experience of Combination Therapy Consisting of Carboplatin, Docetaxel, and Bevacizumab for Previously Treated Advanced Non-small-cell Lung Cancer. Japanese Journal of Lung Cancer, 2010, 50, 901-905.	0.0	1
203	Possibilities of Targeted Therapies for Brain Metastasis. , 2012, , 87-107.		0
204	First-line therapy of advanced non-small cell lung cancer not harboring an activating EGFR mutation. , 2012, , 59-74.		0
206	Brain Metastases. , 2015, , 245-255.		0
207	Therapy options for advanced NSCLC. , 2015, , 5-25.		0
208	Brain Metastases: State of the Art and Innovative Targeted Therapies. Journal of Analytical Oncology, 2015, 4, 113-121.	0.1	0
209	A Case of Cecal Cancer Presented with Solitary Brain Metastasis. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2016, 77, 1994-1999.	0.0	0
210	Cases of Non-small Cell Lung Cancer with Brain Metastases Treated with Bevacizumab in Our Hospital. Japanese Journal of Lung Cancer, 2016, 56, 84-89.	0.0	0
211	Antiangiogenics in Brain Metastases: Perspectives and Experiences. , 2019, , 1-10.		0
212	Anti-angiogenics in Brain Metastases: Perspectives and Experiences. , 2019, , 627-636.		0
213	Bevacizumab Plus Erlotinib in Chinese Patients with Untreated, &lt;i>EGFR&lt;/i>-Mutated, Advanced NSCLC (ARTEMIS-CTONG1509): A Multicenter Phase 3 Study. SSRN Electronic Journal, 0, , .	0.4	3
214	Integrating Systemic Therapy into the Management of Brain Metastases. , 2020, , 95-108.		0
215	MODERN IDEAS ABOUT THE COMBINATION OF RADIATION THERAPY WITH ANTIANGIOGENIC DRUGS IN THE TREATMENT OF PATIENTS WITH BRAIN METASTASES. Siberian Journal of Oncology, 2020, 19, 119-125.	0.1	0
216	SIRT1 is highly expressed in brain metastasis tissues of non-small cell lung cancer (NSCLC) and in positive regulation of NSCLC cell migration. International Journal of Clinical and Experimental Pathology, 2013, 6, 2357-65.	0.5	42
223	Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with -TKIs plus Bevacizumab: A Case Report. Case Reports in Oncology, 2020, 13, 1387-1392.	0.3	1
224	Management of brain metastases in lung cancer: evolving roles for radiation and systemic treatment in the era of targeted and immune therapies. Neuro-Oncology Advances, 2021, 3, v52-v62.	0.4	4
225	Safety and activity of alectinib plus bevacizumab in patients with advanced ALK-rearranged non-small-cell lung cancer: a phase I/II study. ESMO Open, 2022, 7, 100342.	2.0	11

#	ARTICLE	IF	CITATIONS
226	Successful Treatment of Combined Large Cell Neuroendocrine Carcinoma Harboring an EGFR Mutation with <b><i>EGFR</i>-TKIs plus Bevacizumab: A Case Report. Case Reports in Oncology, 2021, 13, 1387-1392.	0.3	5
227	Therapeutic effect of osimertinib plus cranial radiotherapy compared to osimertinib alone in NSCLC patients with EGFR-activating mutations and brain metastases: a retrospective study. Radiation Oncology, 2021, 16, 233.	1.2	8
233	Where Are We Now and Where Might We Be Headed in Understanding and Managing Brain Metastases in Colorectal Cancer Patients?. Current Treatment Options in Oncology, 2022, 23, 980-1000.	1.3	11
234	Bevacizumab-based Salvage Chemotherapy Improves Survival Outcomes for Patients With Brain Metastasis from Ovarian Cancer. Anticancer Research, 2022, 42, 2637-2644.	0.5	3
237	Brain metastasis from colorectal cancer: Treatment, survival, and prognosis. Medicine (United States), 2022, 101, e30273.	0.4	7
238	A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non-â€œsmall cell lung cancer with <i>EGFR</i> mutation. Cancer, 2023, 129, 405-414.	2.0	9
239	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. Journal of Hematology and Oncology, 2022, 15, .	6.9	46
240	Anti-VEGF Therapy Possibly Extends Survival in Patients With Colorectal Brain Metastasis by Protecting Patients From Neurologic Disability. Clinical Colorectal Cancer, 2023, 22, 267-279.	1.0	0